CD8A and neoplasm: In addition, preclinical studies have shown that the anti-tumor long term effect of anti-CD20 treatment is both CD4+ and CD8+ T cell-dependent and requires the presence of NK cells (52, 53, 56), whose expansion correlated with better clinical outcome to RTX treatment (13, 57).